21:00 , Aug 3, 2018 |  BC Extra  |  Company News

Management tracks: Cellectis, Navitor

Zafgen Inc. (NASDAQ:ZFGN) CEO Thomas Hughes has stepped down from the metabolic disease company to become CEO at Navitor Pharmaceuticals Inc. (Cambridge, Mass.). Zafgen is seeking a successor. In June, Navitor begin Phase I testing...
19:30 , Mar 16, 2018 |  BC Week In Review  |  Company News

Athersys, Healios expanding MultiStem deal

Athersys Inc. (NASDAQ:ATHX) and Healios K.K. (Tokyo:4593) entered into a letter of intent (LOI) to expand Healios' license to develop MultiStem products to include treatment of acute respiratory distress syndrome (ARDS) and trauma in Japan....
00:52 , Dec 16, 2017 |  BioCentury  |  Regulation

Growth medium

FDA’s regenerative medicines framework could level the global regulatory playing field for products like cell and gene therapies. It describes approaches to implementing expedited development and review pathways that make them comparable, and in some...
23:07 , Jul 20, 2017 |  BC Innovations  |  Product R&D

Inducing competition for MSCs

In a first for induced pluripotent stem cells, Cynata Therapeutics Ltd. is gearing up to test its iPS cell-derived mesenchymal stem cells in humans, following a favorable pre-IND meeting with FDA. The cells, already in Phase...
23:20 , Apr 7, 2017 |  BioCentury  |  Finance

Taking notice

  Political overhang during the first quarter kept generalists on the sidelines but provided a buying opportunity for life sciences specialists that led the sector to outperform. With “repeal and replace” in the rearview for now...
21:04 , Jan 27, 2017 |  BC Week In Review  |  Financial News

Athersys completes follow-on

On Jan. 27, regenerative medicine company Athersys Inc. (NASDAQ:ATHX) raised $20 million through the sale of 19.8 million shares at $1.01 in a follow-on underwritten by William Blair and Needham. Athersys Inc. (NASDAQ:ATHX), Cleveland, Ohio  ...
08:00 , Feb 22, 2016 |  BC Week In Review  |  Clinical News

MultiStem: Additional Phase II data

Additional data from 126 patients in a double-blind, U.S. and U.K. Phase II trial showed that a single dose of IV MultiStem given 24-48 hours following stroke improved the proportion of patients with an mRS...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Company News

Athersys, Healios deal

Athersys granted Healios exclusive Japanese rights to develop and commercialize MultiStem to treat ischemic stroke. Healios also has an exclusive option to develop and commercialize the product for two additional indications in Japan, including acute...
08:00 , Dec 14, 2015 |  BC Week In Review  |  Company News

Athersys, Chugai deal

Athersys and Chugai terminated a March deal granting Chugai exclusive, Japanese rights to develop and commercialize MultiStem to treat ischemic stroke. Rights will revert to Athersys, which said the parties were unable to reach an...
07:00 , Jul 13, 2015 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg7/10 clsAmgen Inc. (NASDAQ:AMGN)UBSMatthew RodenDowngradeNeutral (from buy)1%$154.10 Roden also lowered his target to $165 from $185 after removing brodalumab from his model. At the end of May, Amgen...